logologo
Search stocks, ETFs, IPOs & more
Quest
arrow

Stock Summary and Key Metrics













Investment Checklist




























Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Ask AI

mockupmockup

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

View Standalone

Total Figures
QoQ Changes
Total Figures
Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2024Sep 2025Dec 2025Mar 2026
Sales0.010.000.000.000.000.000.000.000.000.02
Expenses0.320.350.230.070.080.060.004.943.360.17
Operating Profit-0.31-0.35-0.23-0.07-0.08-0.060.00-4.94-3.36-0.15
OPM %-3,100.00-750.00
Other Income0.040.040.040.040.040.040.000.000.000.03
Interest0.000.000.000.000.000.000.000.000.000.00
Depreciation0.000.000.000.000.000.000.000.000.000.00
Profit Before Tax-0.27-0.31-0.19-0.03-0.04-0.020.00-4.94-3.36-0.12
Tax %0.003.230.0066.670.000.000.000.000.00
Net Profit-0.27-0.30-0.19-0.01-0.04-0.020.00-4.94-3.36-0.12
EPS in Rs-0.12-0.12-0.080.06-0.02-0.010.00-2.00-1.29-0.06

Consolidated Profit Loss (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales1.280.622.011.430.010.020.020.000.000.02
Expenses1.871.734.353.630.920.421.010.250.268.73
Operating Profit-0.58-1.11-2.34-2.19-0.91-0.40-0.99-0.25-0.26-8.72
OPM %-45.63-180.12-116.09-153.27-6,998.23-1,792.60-4,570.37-48,064.81
Other Income0.010.030.110.160.151.910.290.000.000.03
Interest0.000.000.000.000.000.000.000.000.000.00
Depreciation0.010.010.020.020.010.010.000.000.000.00
Profit Before Tax-0.58-1.11-2.35-2.05-0.771.50-0.71-0.25-0.26-8.69
Tax %-123.605.591.143.460.000.000.000.000.000.00
Net Profit-1.31-1.05-2.33-1.98-0.771.50-0.71-0.25-0.26-8.69
EPS in Rs-0.82-0.27
Dividend Payout %0.000.000.000.000.000.000.000.000.000.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital10121415151515151523
Reserves-2.39-0.40-1.61-3.03-3.66-1.58-2.29-2.55-2.84-11
Borrowings6.506.817.928.582.342.742.082.202.431.66
Other Liabilities4.884.746.107.853.081.160.971.091.170.97
Total Liabilities19232628171716161614
Fixed Assets0.460.360.260.130.020.010.010.010.000.00
CWIP151618193.263.263.263.263.262.00
Investments0.010.010.010.014.224.804.804.794.769.84
Other Assets3.926.408.199.089.089.067.507.507.542.54
Total Assets19232628171716161614

Consolidated Cash Flows (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-0.26-3.32-2.96-1.05-0.34-0.400.66-0.13-0.23-4.26
Cash from Investing Activity-1.09-1.19-1.55-1.11-0.230.000.000.000.003.26
Cash from Financing Activity1.274.834.192.170.550.40-0.670.130.222.63
Net Cash Flow-0.080.32-0.320.01-0.020.01-0.00-0.00-0.001.63

Documents

Presentations
Concalls
Reports
Presentations

No documents found!

Actions

Action Type




























































AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Ask AI

ai-corner-premiumai-corner-premium
ai-corner-premiumai-corner-premium

Frequently Asked Questions about Samsrita Labs Ltd

Samsrita Labs Ltd (SAMSRITA) is currently trading at 10.64 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Samsrita Labs Limited, formerly Dr Habeebullah Life Sciences Limited, is engaged in the bio-pharma sector focusing on drug discovery, stem cell therapy, and molecular diagnostics. The company has transitioned from its initial focus on stem cell hospitals to include biopharma activities, emphasized by its historical changes in main business objects to incorporate advanced drug discovery and biotechnology research. It has a strategic collaborative agreement with Krisani Bio Sciences and the Centre for Liver Research and Diagnostics to advance research in NASH and Wilson Disease through revenue-sharing partnerships. The company focuses on affordable healthcare, reflecting its dedication to advancing RNAi therapeutics, biomarker discovery, and other niche biotechnologies. Krisani Bio Sciences transformed from a subsidiary to an associate company, altering Samsrita Labs' ownership stake and highlighting strategic restructuring in shareholding.

Over the past 52 weeks, Samsrita Labs Ltd has traded between a low of ₹10.56 and a high of ₹26.04. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Samsrita Labs Ltd has a market capitalization of approximately 24.21. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Samsrita Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -3.01 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 24.21 Cr, Samsrita Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Samsrita Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Samsrita Labs Ltd is -3.01. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.